Achieving treat to target in gout: a clinical practice improvement project

References

• Chen SY, Chen CL, Shen ML, Kamatani N. Trends in the manifestations of gout in Taiwan. Rheumatology (Oxford) 2003;42: 1529–33.
   PubMed Web of Science ®Google Scholar
• Zeng QY, Chen R, Darmawan J, Xiao ZY, Chen SB, Wigley R, . Rheumatic diseases in China. Arthritis Res Ther 2008;10:R17.
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis 2005;64:267–72.
   PubMed Web of Science ®Google Scholar
• Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology (Oxford) 2007;46:1441–4.
   PubMed Web of Science ®Google Scholar
• Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008;67:1310–16.
   PubMed Web of Science ®Google Scholar
• Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005;118:816–26.
   PubMed Web of Science ®Google Scholar
• Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, . Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 2010;49:141–6.
   PubMed Web of Science ®Google Scholar
• Teng GG, Ang LW, Saag KG, Yu MC, Yuan JM, Koh WP. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis. Published online: 15 December 2011. doi:10.1136/ard.2011.200523.
   Google Scholar
• Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, . Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 2008;67:960–6.
   PubMed Web of Science ®Google Scholar
• Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575–81.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Andrade SE, Briesacher B, Raebel MA, Fouayzi H, Yood RA, . The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med 2010;123:54–9.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, . Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11:R46.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008;67:609–13.
   PubMed Web of Science ®Google Scholar
• Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis 2007;66:1269–70.
   PubMed Web of Science ®Google Scholar
• Khanna D, Ahmed M, Yontz D, Ginsburg SS, Park GS, Leonard A, . The disutility of chronic gout. Qual Life Res 2008;17:815–22.
   PubMedGoogle Scholar
• Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, . EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312–24.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Carmona L, Yebenes MJ, Pascual E, de Miguel E, Urena I, . An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol 2011;17:349–55.
   PubMed Web of Science ®Google Scholar
• Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, . Why don’t physicians follow clinical practice guidelines? A framework for improvement. J Am Med Assoc 1999;282: 1458–65.
   PubMed Web of Science ®Google Scholar
• Bandura A. Social foundations of thought and action: a social cognitive theory. Englewood Cliffs, NJ: Prentice-Hall, 1986.
   Google Scholar
• Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47–56.
   PubMed Web of Science ®Google Scholar
• Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399–416.
   PubMed Web of Science ®Google Scholar
• Health Sciences Authority. 12 August 2009: Serious skin reactions associated with allopurinol (www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/safety_information/product_safety_alerts/safety_alerts_2009/serious_skin_reactions.html). Accessed 19 June 2012.
   Google Scholar
• Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersen- sitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J 2008;49:384–7.
   PubMed Web of Science ®Google Scholar
• Gnanenthiran SR, Hassett GM, Gibson KA, McNeil HP. Acute gout management during hospitalisation: a need for a protocol. Intern Med J 2010;41:610–17.
   Google Scholar
• Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895–900.
   PubMed Web of Science ®Google Scholar
• http:\\www.moh.gov.sg/content/moh_web/home/statistics/Health_Facts_Singapore/Population_And_Vital_Statistics.html. Accessed 19 June 2012.
   Google Scholar
• Stamp LK, O’Donnell JL, Zhang M, James J, Frampton C, Barclay ML, . Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011;63: 412–21.
   PubMed Web of Science ®Google Scholar
• Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, . A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis 2009;68:892–7.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007;57:1324–8.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646–50.
   PubMed Web of Science ®Google Scholar
• Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009;11:135–40.
   PubMedGoogle Scholar
• Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149–53.
   PubMed Web of Science ®Google Scholar
• Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323–7.
   PubMed Web of Science ®Google Scholar
• Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, . HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011;26:3567–72.
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437–43.
   PubMed Web of Science ®Google Scholar
• de Klerk E, van der Heijde D, Landewe R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44–54.
   PubMed Web of Science ®Google Scholar
• Ng DY, Stocker SL, Graham GG, Williams KM, Day RO. Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers. Eur J Clin Pharmacol 2010;67:709–13.
   Google Scholar
• Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol 2008;35:498–501.
   PubMed Web of Science ®Google Scholar
• Keenan RT, Lehman RA, O’Brien WR, Crittenden DB, Lee KH, Pillinger MH. Gout management in primary care vs. rheumatology: evidence for suboptimal treatment. Arthritis Rheum 2009; 60(S):415.
   Google Scholar
• Stewart RE, Vroegop S, Kamps GB, van der Werf GT, Meyboom-de Jong B. Factors influencing adherence to guidelines in general practice. Int J Technol Assess Health Care 2003;19:546–54.
   Google Scholar
• Weijer C, Grimshaw JM, Taljaard M, Binik A, Boruch R, Brehaut JC, . Ethical issues posed by cluster randomized trials in health research. Trials 2011;12:100.
   PubMed Web of Science ®Google Scholar
• Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: Short Form-36 is responsive to change in chronic gout. Rheumatology (Oxford) 2011;50:740–5.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356–60.
   PubMed Web of Science ®Google Scholar